Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study
Main finding · AKI occurrenceResult — go to the resultHazard ratio 0.67 95% CI 0.55–0.81Authors' conclusion
DXM was associated with a decrease in the risk of AKI in severe COVID-19 patients admitted to ICU.
Study context
- Population
- Intensive care unit (ICU) patients with severe COVID-19 without preexistent acute kidney injury (AKI) or prior dexamethasone (DXM), three French ICUs, March 2020–August 2021
- Participants
- 798 patients
- Exposure
- DXM vs no DXM at ICU entry
- Outcome
- Occurrence of AKI
Methodological detailsthree French ICUs, multivariate cause-specific Cox models
- Three French ICUs
- Multivariate cause-specific Cox models
Main finding
AKI occurrence
Hazard ratio
0.67
95% CI 0.55–0.81
DXM vs Without DXM
HR 0.67 (95% CI 0.55–0.81)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Sensitivity analyses (excluding DXM-to-AKI delay <12 h; accounting for pandemic waves)
- Results consistent
Original publication
Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study. Ann Intensive Care. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →